Search

Your search keyword '"NEURAMINIDASE"' showing total 334 results

Search Constraints

Start Over You searched for: Descriptor "NEURAMINIDASE" Remove constraint Descriptor: "NEURAMINIDASE" Journal antiviral research Remove constraint Journal: antiviral research
334 results on '"NEURAMINIDASE"'

Search Results

1. Mosaic neuraminidase-based vaccine induces antigen-specific T cell responses against homologous and heterologous influenza viruses.

2. Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022–2023 influenza season in Japan.

3. Anti-influenza activity of CPAVM1 protease secreted by Bacillus subtilis LjM2.

4. hnRNPAB inhibits Influenza A virus infection by disturbing polymerase activity.

5. Low antiviral resistance in Influenza A and B viruses isolated in Mexico from 2010 to 2023.

6. Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults.

7. Supplementation of seasonal vaccine with multi-subtype neuraminidase and M2 ectodomain virus-like particle improves protection against homologous and heterologous influenza viruses in aged mice.

8. Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022–2023 season.

9. Promises and challenges of single-domain antibodies to control influenza.

10. Broadly neutralizing antibodies to combat influenza virus infection.

11. Discovery of new antiviral agents through artificial intelligence: In vitro and in vivo results.

12. Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir.

13. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.

14. Potent and broad-spectrum cycloheptathiophene-3-carboxamide compounds that target the PA-PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance.

15. Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012–2018.

16. Novel influenza inhibitors designed to target PB1 interactions with host importin RanBP5.

17. New insights into the neuraminidase-mediated hemagglutination activity of influenza A(H3N2) viruses.

18. Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses.

19. Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022.

20. Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models.

21. Neuraminidase inhibitors susceptibility profiles of highly pathogenic influenza A (H5N1) viruses isolated from avian species in India (2006–2015).

22. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017.

23. Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014–2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.

24. Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses.

25. Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility.

26. A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment.

27. The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.

28. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015–2016.

29. Characterization of oseltamivir-resistant influenza virus populations in immunosuppressed patients using digital-droplet PCR: Comparison with qPCR and next generation sequencing analysis.

30. Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.

31. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020

32. An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance

33. Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors

34. Influenza antivirals and their role in pandemic preparedness.

35. Thermodynamic and structural characterization of an optimized peptide-based inhibitor of the influenza polymerase PA-PB1 subunit interaction.

36. An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance.

37. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.

38. Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects.

39. Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance.

40. Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.

41. The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models.

42. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015.

43. Influenza A and methicillin-resistant Staphylococcus aureus co-infection in rhesus macaques – A model of severe pneumonia.

44. Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.

45. New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase

46. Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development

47. Analysis of the responsible site for favipiravir resistance in RNA-dependent RNA polymerase of influenza virus A/PR/8/34 (H1N1) using site-directed mutagenesis.

48. Catalytic mechanism and novel receptor binding sites of human parainfluenza virus type 3 hemagglutinin-neuraminidase (hPIV3 HN).

49. Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells.

50. Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.

Catalog

Books, media, physical & digital resources